Objective: This study aims to test the added value of calcium and vitamin D (CaD) in fracture prevention among women taking postmenopausal hormone therapy (HT).
C ontroversy surrounds the use of supplemental calcium and vitamin D (CaD). The literature is full of conflicting reports and strong opinions. Major authorities have questioned the health benefits/risks of widespread supplementation. 1 The US Preventive Services Task Force 2 recently published recommendations advising against routine supplementation with CaD.
In practice, most trials of osteoporosis medications have included CaD supplementation for both active and placebo groups. 3 Little data support this practice. Conflicting results have been published from prior trials. One publication looking at response to bisphosphonates showed improved response in bone mineral density (BMD) and turnover markers with higher vitamin D serum levels. 4 Using data from the Fracture Intervention Trial of alendronate, Antoniucci et al 5 showed that baseline vitamin D levels did not change outcomes. Looking at a relatively small number of participants in zolentonate trials, an Australian group was unable to show a statistically significant effect of either dietary CaD or vitamin D levels on BMD or turnover makers. 6 Another recent publication only showed a response among those with initially low vitamin D levels. 7 The use of postmenopausal hormones is also controversial. Some groups support the use of estrogen therapy for the treatment of osteoporosis, 8 although it may not be considered the standard of care.
Women's Health Initiative (WHI) clinical trials that did not select women based on low bone density or osteoporosis demonstrated that estrogen therapy, with or without progestin, increased bone density and reduced fracture risk similarly. 9, 10 In this article, we address two major research questions: (1) Does CaD supplementation increase bone health benefits in postmenopausal women on estrogen therapy? (2) Does estrogen therapy increase bone health benefits in women taking CaD supplementation?
The WHI offers a unique opportunity to address these questions through secondary analyses of data from prospective, partial-factorial, randomized trials. The WHI used a partialfactorial design for two hormonal trials (conjugated equine estrogens [CEE] alone and CEE + medroxyprogesterone acetate [MPA]) and for a trial of CaD supplementation. 11 This permits the exploration of the effects of CaD on hip fractures in women receiving hormonal supplementation in a double-blind prospective study, and vice versa.
Women were randomized to either, both, or neither of the hormonal and CaD trials. After the hormone therapy (HT) intervention ended, only a small percentage of participants reported using HT; less than 5% of women in the active arms and less than 3% of women in the placebo arms of either WHI HT trial continued to take hormones. 12 Incident hip fracture outcomes were assessed and adjudicated by investigators blinded to treatment assignments. 13 Four clinical sites assessed BMD in a subsample of women, using dual-energy x-ray absorptiometry (DXA), at baseline and on years 1, 3, and 6 after HT randomization.
METHODS
The WHI recruited postmenopausal women aged 50 to 79 years from 40 US clinical centers between 1993 and 1998. Women with intact uterus had 0.625 mg of CEE combined with 2.5 mg/day MPA compared with placebo, and women who had a hysterectomy had 0.625 mg/day CEE compared with placebo. Women were simultaneously recruited to participate in a distinct overlapping randomized controlled intervention, the WHI dietary modification (DM) trial. Participants enrolled in either the DM trial, the HT trial, or both were invited to join the CaD trial at their first or second annual follow-up visit ( Fig. 1 ). Those who consented were randomized to either 1,000 mg/day elemental calcium as calcium carbonate plus 400 IU of vitamin D 3 daily or placebo.
Detailed descriptions of eligibility criteria and recruitment methods have been published. 11 DM participants are included in this analysis because some of them were randomized to CaD and contribute to the comparison of CaD with placebo.
FIG. 1. Consort diagram of the Women's Health Initiative (WHI) clinical trial. All 68,132 women were included in the analysis, with survival time beginning at randomization into hormone therapy (HT), dietary modification (DM), or both. Women were later randomized to calcium and vitamin D (CaD) on years 1 and 2, or did not participate in the CaD trial. Hip fracture incidence and summary statistics, from CaD randomization through study close-out (March 31, 2005) , are summarized in Table 2 .
Hip fractures were evaluated through the originally specified date of trial completion, March 31, 2005. Hip and other fractures were self-reported semiannually. Hip fractures were verified by a review of radiographic reports, operative reports, or both by blinded physician adjudicators.
We combined the fracture outcomes of the two hormone arms. We postulated that the effect on fracture is predominantly mediated by the CEE component of the therapy and, thus, was similar. The original publications reporting hip fracture rates in the two arms of the HT gave very similar results: the hazard ratio (HR) (95% CI) of CEE + MPA for hip fracture compared with placebo was 0.66 (0.45-0.98), and that of CEE alone was 0.61 (0.41-0.91). 14, 15 Some previous studies also suggested similar effects of CEE and CEE + MPA on bone, 16 whereas other studies on a modified intent-to-treat protocol noted increases in spine BMD, with the addition of MPA. 17 Because of these conflicting results, we validated the decision to combine the groups by examining changes in BMD among women in the active therapy arms of the two HT trials and found the effects of CEE alone and CEE + MPA to be similar (Appendix).
Women in the CaD trial were permitted to take their own CaD supplementation. Information regarding the amounts of dietary CaD intake and personal supplementation was available from baseline questionnaires. Combing self-reported intake with trial intakes permitted us to investigate a larger range of total CaD intake, in conjunction with HT, in relation to hip fracture incidence.
A subset of women in the WHI had BMD measured at three clinical centers (four sites): Birmingham, AL; Pittsburgh, PA; Tucson, AZ; and Phoenix, AZ. They were chosen to provide maximal racial diversity and were not representative of CT as a whole. DXA (Hologic QDR 2000 or 4500W), using standard protocols for positioning and analysis, was used to assess BMD at the hip, spine, and total body at baseline and on years 1, 3, and 6 of follow-up. Demographic profiles between the entire cohort and this subset were similar. All DXA technicians were trained and certified by the DXA manufacturer and by the WHI BMD coordination center at the University of California at San Francisco.
Research protocols were approved by the universities' human subjects committees.
Statistical methods
Primary analyses included all 68,132 randomized participants in the WHI clinical trials, using time-to-event methods through study close-out (March 31, 2005), and were based on the intent-to-treat principle. HRs for hip fracture were estimated from a proportional hazards model that included a categorical variable for HT (active/placebo/not randomized), a similar time-dependent categorical variable for CaD, and their corresponding interaction terms. Models were stratified by prevalent condition, 5-year age group, DM randomization arm and hysterectomy status, and event times that began upon randomization to the HT or DM trial.
We conducted a sensitivity analysis in which we censored HT trial participants at the time that the HT interventions ended (July 7, 2002 for the CEE + MPA trial and February 29, 2004 for the CEE trial). Although we focused on the 2 Â 2 factorial portion of HT (active vs placebo) Â CaD (active vs placebo), the inclusion of women who were not randomized ensures that the estimated main effects in these analysis correspond to estimates that would have been obtained if the complete trials were examined individually; designs for these individual trials have been previously published. 14, 15 We planned analyses a priori according to baseline subgroups of age (G60 or Q60 y), total calcium intake (G600, 600 to G1,200, or Q1,200 mg), and HT personal use at baseline. Statistical significance of the subgroup analysis was based on the P value for interaction.
Further analysis of the effect modification of HT by CaD was performed by creating a time-dependent quasi subgroup of self-reported nutrient intake at baseline that was updated at CaD randomization by adding the nutrients associated with study pills. The effect of HT was allowed to vary continuously with nutrient values as a spline, with a smoothing parameter chosen objectively through generalized cross-validation and statistical significance based on the test of interaction. Adherence sensitivity analyses of the primary analysis were conducted by censoring follow-up beginning 6 months after the participants became nonadherent. Separate analyses were performed at adherence thresholds that corresponded to ingestion of less than 50% and less than 80% of CaD study pills.
Cumulative hazard functions for the 2 Â 2 factorial were computed using Simon-Makuch estimates to accommodate time-dependent randomization into the CaD trial. 18 At time 0, all participants begin in the group Bnot randomized to CaD/ active HT[ or Bnot randomized to CaD/placebo HT.[ Participants are later allowed to change groups after randomization into the CaD trial. Longitudinal change in BMD was evaluated in the 2 Â 2 factorial among women in the BMD subsample. The within-individual correlation was accounted for in a repeated-measures regression model with an unstructured correlation matrix.
Baseline characteristics for women in the 2 Â 2 factorial were compared by randomization group using W 2 test and t test. Annualized rates of clinical events were estimated by dividing the number of events by person-time. All statistical analyses were conducted using SAS software version 9.2 (SAS Institute Inc, Cary, NC) and R software version 2.11 (R Foundation for Statistical Computing; http://www. r-project.org/). All statistical tests were two-sided.
RESULTS
Baseline characteristics by CaD and HT randomization arms are displayed in Table 1 . With the exception of the clinically insignificant difference in mean ages across randomization groups, risk factors were similar.
For the primary outcome of hip fracture, after a mean (SD) follow-up of 7.2 (1.4) years from CaD randomization, there was a significant interaction between HT and CaD (P interaction = 0.01; Table 2 ). The effect of HT (active vs placebo) on hip fracture prevention was stronger among women assigned to active CaD (HR, 0.43; 95% CI, 0.28-0.66) than among women assigned to placebo (HR, 0.87; 95% CI, 0.60-1.26). Likewise, the effect of CaD (active vs placebo) was stronger among women assigned to active HT (HR, 0.59; 95% CI, 0.38-0.93) than among women assigned to placebo (HR, 1.20; 95% CI, 0.85-1.69). Plots of cumulative hazards display the synergistic effect of being on both active therapies compared with each individual therapy alone (Fig. 2) . Although the HT interventions stopped before the 2005 closeout, the main effect of HT was still protective at the end of the study period (HR, 0.76; 95% CI, 0.62-0.93).
In a sensitivity analysis that censored participants once the HT intervention ended, the main effect of HT became stronger (HR, 0.67; 95% CI, 0.52-0.86), and the effect of HT on hip fracture prevention was greater among women assigned to active CaD (HR, 0.46; 95% CI, 0.27-0.80) than among women assigned to placebo CaD (HR, 0.78; 95% CI, 0.49-1.26) after a mean (SD) follow-up of 5.2 (1.4) years. However, this sensitivity analysis was limited by 40% fewer hip fracture cases (129 vs 214); the interaction between HT and CaD was not statistically significant (P interaction = 0.15; Appendix, Table 1 ).
The interaction between HT and CaD translates into 11 hip fractures per 10,000 person-years for women assigned to both active HT and active CaD compared with 18 per 10,000 person-years for women assigned to active HT only, 25 per 10,000 person-years for women assigned to active CaD only, and 22 cases per 10,000 person-years in those assigned to both placebo arms (hip fractures per year in the placebo and CaD arms are not statistically different).
The subgroup analysis of baseline total personal calcium intake showed a pattern similar to that in Table 2 : the benefit of CaD (active vs placebo) on hip fracture prevention was enhanced among women taking HT compared with women on placebo for all categories of baseline calcium intake. The benefit of HT on hip fracture prevention was enhanced among women randomized to CaD, regardless of the subgroup of personal calcium intake, indicating that the synergistic interaction of HT and CaD was consistent across all levels of personal calcium intake (P trend = 0.86; data not shown). This observation was further supported when baseline levels of nutrient intakes and study pills were considered together. The   FIG. 2. Cumulative hazards for the incidence of hip fracture by hormone therapy (HT) and calcium and vitamin D (CaD) randomization. Cumulative hazard functions of hip fracture that allow for randomization into the CaD trial as a time-dependent variable. (95% CI) 0.59 (0.38-0.93) 1.20 (0.85-1.69) P interaction = 0.01 Summary statistics for women not randomized to HT or CaD are not shown. Events are through March 31, 2005. Time to event equals zero at the time of HT randomization. HR (active HT vs placebo HT) by CaD randomization group: HR (95% CI) for main effect of HT, 0.76 (0.62-0.93); HR (95% CI) among women not randomized to CaD, 0.94 (0.70-1.26). HR (active CaD vs placebo CaD) by HT randomization group: HR (95% CI) for main effect of CaD, 0.87 (0.72-1.07); HR (95% CI) among women not randomized to HT, 0.83 (0.62-1.12). HR, hazard ratio; WHI, Women's Health Initiative; HT, hormone therapy; CaD, calcium and vitamin D. a HRs from a proportional hazards model were fitted to the entire WHI clinical trial (n = 68,132) and included a time-dependent categorical variable (not randomized/placebo/active) for CaD, an indicator variable for HT, and their corresponding interaction term. Models were stratified by prevalent condition (hip fracture after the age of 55 y), 5-year age group, dietary modification, randomization arm, and hysterectomy status. beneficial effect of HT was evident at about 1,200 mg of baseline personal Ca use and continued to increase thereafter (P interaction = 0.006; Fig. 3A) . Similarly, the benefit of HT continued to increase at levels higher than 400 IU of vitamin D (P interaction = 0.02; Fig. 3B ).
There were too few cases to reliably test whether the synergistic effects of HT Â CaD were consistent across subgroups of age and self-reports of prior menopausal hormone use at baseline (yes/no); there were only 20 hip fracture cases among women younger than 60 years. There were only 13 hip fracture cases among women reporting personal use of menopausal HT at baseline. At the 0.05 level of significance, less than one interaction P value could be statistically significant based on chance alone.
Adherence analyses of those who took more than 50% or 80% of the allocated CaD therapy or placebo suggested the same synergistic pattern of HT Â CaD, but the synergistic pattern was not statistically significant at either threshold (P interaction 50% = 0.17; P interactions 80% = 0.85). We suspect that the smaller sample size in the adherence analyses may have limited our power to detect statistically significant associations.
We found no evidence for the potential interactions of CaD and postmenopausal HT in relation to total fractures (P interactions = 0.97) or clinical vertebral fractures (P interactions = 0.79; data not shown).
The intermediate endpoint of BMD was investigated in 1,058 (261, active HT/active CaD; 275, active HT/placebo; 272, placebo/ active CaD; 250, placebo/placebo) women who were randomized in the CaD and HT trials. Percent change in BMD of the total hip is presented in Figure 4 . There was no evidence of a synergistic effect between estrogen therapy and CaD on hip BMD (P interactions = 0.79) or spine BMD (data not shown).
DISCUSSION
The previously published WHI article on CaD supplementation and risk of fractures found no overall significant benefit of CaD upon intent-to-treat analysis. Our further investigation of the WHI data shows that CaDValthough, by itself, may not be of statistically proven benefit for fracture preventionVmay have a significant effect when used with HT. The current study provides evidence that supplemental CaD augments the protective effects of HT against hip fracture, and vice versa.
We were able to show an interaction of CaD and HT only for hip fractures. We postulate that this is a function of the imprecise diagnosis of nonhip fractures. The endpoint of hip fracture is very precise because it is based on hospitalization. It is well documented that the diagnosis of vertebral fractures is inaccurate. 20 We believe that this imprecision in outcomes translated into too much Bnoise[ to permit an accurate evaluation of the interaction of CaD and HT. One could also speculate that the effect of HT is differentially modified by CaD on certain bone sites, and vice versa, but we have no way of evaluating this.
Although these data do not allow us to define a specific optimal threshold for CaD intake, both subgroup analyses regarding CaD intake suggest higher benefits of HT on hip fracture risk reduction associated with increased intake of CaD. In the subgroup analysis of baseline calcium, the benefit of HT was larger for women randomized to CaD than for those given placebo for all subgroups of baseline calcium intake. On total calcium intake, the benefit of HT had a strong positive association with total calcium intake greater than 1,200 mg. A similar positive association was observed with vitamin D intake. We found no evidence for an upper limit to the hip fracture risk reduction associated with calcium or vitamin D among women taking HT.
Women in the WHI were not specifically recruited based on BMD or diagnosis of osteoporosis. Many of those tested in the BMD subgroup had BMD within the reference range. Nonetheless, supplementation with CaD decreased the risk of hip fracture in postmenopausal women assigned to HT. For the entire cohort, CaD supplementation in the WHI was not sufficient on an intent-to-treat analysis to show a statistically significant decrease in hip fractures when it was not combined with postmenopausal HT. A sensitivity analysis of adherent women showed an effect of CaD supplementation on older women and those most adherent to their study pills.
Although only a subset of women in the WHI was evaluated by DXA, visual comparison of the profile plots of the mean changes in hip BMD suggests no interaction because the profiles are decidedly additive. The actions of HT and CaD on hip fracture prevention may be mediated through mechanisms other than increased BMD. These potential mechanisms could include improved balance, muscle strength, bone architecture, and bone strength, among others.
The study also has limitations. Because of the combined nature of the CaD intervention, we are unable to separate the effects of the specific components. Our ability to estimate required CaD doses is limited by the self-report of information regarding CaD intake, instead of directly observed intake. The women in the WHI probably have higher dietary CaD intake than the average postmenopausal women, which should have been expected to bias the results toward the null. We also lacked information regarding sun light exposure. Blood vitamin D levels were not measured for most of the study participants; therefore, personal intake of vitamin D may not reflect actual circulating values.
The strengths of this study include its large sample size (915,000 women), extensive information regarding dietary intakes, and randomized controlled trial study design. Compared with prior studies, the partial-factorial design of the current study gives it more strength to evaluate the effects of CaD on hip fracture risk in women on CEE.
CONCLUSIONS
These results suggest that women taking postmenopausal estrogens should also take supplemental CaD. Because of the study design, we are unable to suggest a specific level of supplementation; benefit seems to increase with increasing total CaD intake. Dose choice should be made to minimize adverse effects. It may be possible to extrapolate to women taking other forms of osteoporosis therapy, suggesting that they also take CaD supplementation. However, we have no evidence for this, and further research is obviously needed.
